Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

PYC Therapeutics Ltd

Healthcare AU PYC

1.495AUD
0.03(1.70%)

Last update at 2026-03-11T05:10:00Z

Day Range

1.461.50
LowHigh

52 Week Range

0.831.71
LowHigh

Fundamentals

  • Previous Close 1.47
  • Market Cap1412.23M
  • Volume450999
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-51.40844M
  • Revenue TTM20.56M
  • Revenue Per Share TTM0.04
  • Gross Profit TTM 20.56M
  • Diluted EPS TTM-0.08

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -51.01317M -55.66977M -23.35648M -14.29397M -18.63000M
Minority interest 0.71M 0.39M 0.57M 0.43M 0.88M
Net income -50.30468M -37.72541M -22.78899M -14.32656M -20.93958M
Selling general administrative 7.07M 4.51M 2.54M 4.38M 6.18M
Selling and marketing expenses - - - - -
Gross profit 23.49M 22.06M 15.81M - -
Reconciled depreciation 0.60M 0.60M 0.55M 0.84M 0.62M
Ebit -53.62784M -55.62056M -23.32919M -14.26137M -18.59118M
Ebitda -52.87530M -54.55280M -22.77797M -13.42187M -17.96882M
Depreciation and amortization 0.75M 1.07M 0.55M 0.84M 0.62M
Non operating income net other - - - - -
Operating income -53.62784M -38.85723M -23.43091M -14.26137M -18.59118M
Other operating expenses 77.12M 60.92M 39.22M 30.21M 21.83M
Interest expense 0.06M 0.05M 0.03M 0.03M 0.04M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 2.68M 0.80M 0.08M 0.02M 0.11M
Net interest income 2.61M 0.75M 0.05M -0.00817M 0.07M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -23.49435M -17.55931M -0.56749M 0.03M 2.31M
Total revenue 23.49M 22.06M 15.81M 16.07M 3.08M
Total operating expenses 77.12M 60.92M 39.16M 30.21M 21.83M
Cost of revenue - 1.07M - - -
Total other income expense net 2.61M -16.81255M 15.75M -0.03259M -0.03882M
Discontinued operations - - - - -
Net income from continuing ops -51.01317M -38.11046M -23.35648M -14.29397M -18.63000M
Net income applicable to common shares -50.30468M -37.72541M -22.78899M -13.86316M -17.76759M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 183.28M 91.24M 37.17M 45.35M 57.94M
Intangible assets 3.85M - 4.25M 4.45M 4.65M
Earning assets - - - - -
Other current assets 0.41M 0.74M 0.05M 0.07M 0.09M
Total liab 13.27M 10.18M 8.72M 5.15M 4.02M
Total stockholder equity 169.57M 80.50M 27.75M 39.35M 52.54M
Deferred long term liab - - - - -
Other current liab - 1.27M 3.49M 1.81M 0.95M
Common stock - 230.58M 140.09M 125.99M 125.99M
Capital stock 369.59M - 140.09M 125.99M 125.99M
Retained earnings -206.19953M -155.89485M -118.16944M -95.38045M -81.51729M
Other liab - - 0.18M 0.08M 0.18M
Good will - - - - -
Other assets - - 0.00000M 0.02M 0.02M
Cash 153.05M 66.87M 15.57M 29.11M 18.44M
Cash and equivalents - - 15.57M 29.11M 18.44M
Total current liabilities 12.32M 9.11M 8.41M 4.39M 3.30M
Current deferred revenue - - -0.17782M -0.25980M -0.18753M
Net debt - -65.76179M -15.25605M -28.16626M -17.70484M
Short term debt - 0.31M 0.18M 0.26M 0.19M
Short long term debt - - - - -
Short long term debt total - 1.11M 0.32M 0.94M 0.73M
Other stockholder equity - - -21.91791M -30.61088M -44.47404M
Property plant equipment - - 1.04M 1.63M 1.49M
Total current assets 177.53M 85.61M 31.87M 39.25M 51.78M
Long term investments - - - - -
Net tangible assets - - 23.50M 34.90M 48.39M
Short term investments - - - 0.00000M 33.07M
Net receivables - 18.00M 16.25M 10.07M 0.19M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 8.75M 7.53M 4.92M 2.57M 2.35M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 5.81M 5.83M 8.74M 8.07M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 4.05M -5.29275M 0.02M 0.02M
Deferred long term asset charges - - - - -
Non current assets total 5.75M 5.62M 5.29M 6.10M 6.16M
Capital lease obligations 1.02M - 0.32M 0.94M 0.73M
Long term debt total - - 0.14M 0.68M 0.54M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -0.97540M -0.30704M -0.47712M 33.07M -14.88134M
Change to liabilities - - 4.34M 0.26M 2.50M
Total cashflows from investing activities -0.97540M -0.30704M -0.47712M 32.68M -15.52169M
Net borrowings - - -0.23279M -0.18236M -0.22664M
Total cash from financing activities 138.66M 90.19M 11.44M -0.18236M 38.56M
Change to operating activities - - -0.13995M 0.53M 0.22M
Net income -50.30468M -37.72541M -22.78899M -13.86316M -17.76759M
Change in cash 86.18M 51.30M -13.53849M 10.67M 11.19M
Begin period cash flow 66.87M 15.57M 29.11M 18.44M 7.24M
End period cash flow 153.05M 66.87M 15.57M 29.11M 18.44M
Total cash from operating activities -51.56008M -38.58850M -24.42169M -21.78228M -11.79131M
Issuance of capital stock 145.82M 92.06M 12.65M - 41.08M
Depreciation - 1.07M 0.88M 0.84M 0.62M
Other cashflows from investing activities - 0.00000M 0.01M 33.07M -0.04932M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -5.73606M -2.43831M -6.16265M -9.83360M -0.13333M
Sale purchase of stock -6.80244M -1.56875M -0.97625M -0.97625M -2.29467M
Other cashflows from financing activities -6.80244M -0.29448M -0.23279M -0.18236M -0.22664M
Change to netincome - - -0.55422M 0.18M 2.77M
Capital expenditures 0.98M 0.31M 0.49M 0.39M 0.59M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -2.56027M -2.15991M -6.16265M -9.83360M -0.13333M
Stock based compensation - 0.25M -0.07030M 0.61M 3.63M
Other non cash items -48.99981M 0.23M -2.51475M -8.75907M 5.35M
Free cash flow -52.53548M -38.89554M -24.91280M -22.16919M -12.38234M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PYC
PYC Therapeutics Ltd		 0.03 1.70% 1.50 - 12.00 68.69 9.50 25.02 -8.4071
CSL
CSL Ltd		 -1.98 1.37% 142.58 16.70 19.49 4.61 2.68 3.87 11.63
TLX
TELIX Pharmaceuticals Ltd		 -0.24 2.18% 10.76 - 1000.00 4.25 5.68 3.34 76.39
MSB
Mesoblast Ltd		 0.01 0.46% 2.19 - 454.55 43.02 3.19 28.08 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.2 1.57% 12.55 53.70 45.66 24.19 4.61 19.56 57.40

Reports Covered

Stock Research & News

View All

Profile

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for treating blinding eye disease named Autosomal Dominant Optic Atrophy, which is in clinical studies; PYC-002, a drug program for the treatment of severe neurodevelopmental disorder named Phelan-McDermid Syndrome, which is in pre-clinical studies; and PYC-003 to treat autosomal dominant polycystic kidney disease, which is in early-stage clinical trials. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.

PYC Therapeutics Ltd

Harry Perkins Institute of Medical Research, Nedlands, WA, Australia, 6009

Key Executives

Name Title Year Born
Dr. Rohan Hockings G.D.L.P, J.D., MBBS, MBBS (Hons.) CEO & Exec. Director 1983
Mr. Andrew Taylor B.Com., C.A. Chief Financial Officer NA
Prof. Sue Fletcher Chief Scientific Officer NA
Dr. May Orfali M.B.A., M.D. Chief Medical Officer of US Operations 1968
Dr. Glenn Noronha Chief Devel. Officer 1965
Mr. Kevin Ronald Hart B.Com, B.Comm (Hons), C.A., F.C.A., FCA Company Sec. 1962
Dr. Rohan Hockings G.D.L.P, J.D., MBBS, MBBS (Hons.) CEO & Executive Director 1983
Mr. Andrew Taylor B.Com., C.A. CFO & Company Secretary NA
Mr. Kevin Ronald Hart B.Com., B.Comm (Hons), C.A., F.C.A. Company Secretary 1962
Dr. Rohan Hockings G.D.L.P, J.D., MBBS, MBBS (Hons.) CEO & Executive Director 1983

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.